Last Updated : February 28, 2014
Details
FilesGeneric Name:
Ranibizumab
Project Status:
Complete
Therapeutic Area:
Myopic choroidal neovascularisation
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Lucentis
Project Line:
Reimbursement Review
Project Number:
SR0373-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Choroidal neovascularisation, myopic
Recommendation Type:
List with criteria/condition
Final Recommendation:
Files
Last Updated : February 28, 2014